The UK and US have reached a key trade agreement that will maintain no levies on UK medicine products going into the US market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has agreed to boost funding on medicines through the National Health Service (NHS). This pledge guarantees that tariffs on these key products will remain at nothing for a period of three years.
This deal follows recent statements to dramatically increase import taxes on patented pharmaceutical imports, with increases discussed as high as one hundred percent.
"This agreement between the UK bolsters the global environment for innovative medicines and establishes much-needed equity to U.S.–U.K. drug exports," an announcement declared.
Economic Impact
Drugs are one of the UK's biggest exports to the US, which is clearly the largest destination for large British pharmaceutical firms.
Trade data indicate that in the one-year period prior to last September, the UK exported medicines totaling billions to the US. This amount represented nearly one-fifth of total UK exports in that timeframe.
"This agreement protects jobs, stimulates capital expenditure and facilitates the UK to become a global hub for biotech and pharma," a minister commented.
Detailed British Pledges
The agreement involves several specific commitments from the United Kingdom:
- Price Threshold Increase: The UK will raise the affordability limit at which it judges new treatments to be unaffordable by 25%.
- Increased NHS Spending: There is a goal to double overall health service expenditure on treatments from 0.3% of Gross Domestic Product to 0.6% over the next decade.
- Refund Ceiling: The percentage pharmaceutical firms must refund to the NHS to control costs will be capped at 15%. Previously, rebates were more than twenty percent.
Industry Background
The pact comes amid a protracted dispute between the drug companies and the British authorities over drug pricing and approval rates.
These tensions were exacerbated by arguments that US consumers were charged a premium for the equivalent treatments than patients in the UK and Europe.
In recent months, several large drug company projects in the UK have been halted or scrapped, while substantial investments have been directed toward projects in the United States.
The Science Minister acknowledged that the NHS had to increase expenditure on drugs, noting that its spending on drugs had declined as a share of its overall budget over the last ten years.
